Assessing orally bioavailable commercial silver nanoparticle product on human cytochrome P450 enzyme activity

References

• Arora S, Jain J, Rajwade JM, Paknikar KM. 2009. Interactions of silver nanoparticles with primary mouse fibroblasts and liver cells. Toxicol Appl Pharmacol 236:310–18
   PubMed Web of Science ®Google Scholar
• Atiyeh BS, Costagliola M, Hayek SN, Dibbo SA. 2007. Effect of silver on burn wound infection control and healing; review of the literature. Burns 33:139–48
   PubMed Web of Science ®Google Scholar
• Barrie HJ, Harding HD. 1947. Argyro-siderosis of the lungs in silver finishers. Br J Ind Med 4:225–32
   PubMedGoogle Scholar
• Becker H, Herzberg F, Schulte A, Kolassa-Gehring M. 2011. The carcinogenic potential of nanoparticles, their release from products and options for regulating them. Int J Hyg Environ Health 214:231–8
   PubMed Web of Science ®Google Scholar
• Behra R, Sigg L, Clift MJD, Herzog F, Minghetti M, Johnston B, et al. 2013. Bioavailability of silver nanoparticles and ions: from a chemical and biochemical perspective. J R Soc Interface 10:20130396. doi: 10.1098/rsif.2013.0396
   PubMed Web of Science ®Google Scholar
• Bhol KC, Alroy J, Schechter PJ. 2004. Anti-inflammatory effects of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model. Clin Exp Dermatol 29:282–7
   PubMed Web of Science ®Google Scholar
• Carlson C, Hussain SM, Schrand AM, Braydich-Stolle LK, Hess KL, Jones RL, Schlager JJ. 2008. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J Phys Chem B 112:13608–19
   PubMed Web of Science ®Google Scholar
• Choi O, Clevenger TE, Deng B, Surampalli RY, Ross L Jr, Hu Z. 2009. Role of sulfide and ligand strength in controlling nanosilver toxicity. Water Res 43:1879–86
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim JK, Eunmi B, Park JS, Cim CK. 2008. Determination of losartan in human plasma by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS): application to bioequivalence study. J Liq Chromat Relat Technol 31:2643–56
   Web of Science ®Google Scholar
• Christen V, Fent K. 2012. Silica nanoparticles and silver-doped silica nanoparticles induce endoplasmatic reticulum stress response and alter cytochrome P4501A activity. Chemosphere 87:423–34
   PubMed Web of Science ®Google Scholar
• Chung IS, Lee MY, Shin DH, Jung HF. 2010. Three systemic argyria cases after ingestion of colloidal silver solution. Int J Dermatol 49:1175–7
   PubMed Web of Science ®Google Scholar
• Drake PL, Hazelwood KJ. 2005. Exposure-related health effects of silver and silver compounds: a review. Ann Occup Hyg 49:575–85
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjőgren T. 2006. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682–7
   PubMed Web of Science ®Google Scholar
• Elechiguerra JL, Burt J, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. 2005. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 3:6. doi: 10.1186/1477-3155-3-6
   PubMedGoogle Scholar
• Espinal ML, Ferrando L, Jimenex DF. 1996. Asymptomatic blue nevus-like macule. Diagnosis: localized argyria. Arch Dermatol 132:461–4
   PubMedGoogle Scholar
• Frőhlich E, Kucznik T, Samberger C, Roblegg E, Wrighton C, Pieber TR. 2010. Size-dependent effects of nanoparticles on the activity of cytochrome P450 enzymes. Toxicol Appl Pharmacol 242:326–32
   PubMed Web of Science ®Google Scholar
• Frőhlich E. 2013. Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles. Curr Drug Metab 14:976–88
   PubMed Web of Science ®Google Scholar
• Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, et al. 2010. An evaluation of the drug interaction potential of pazopanib and oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652–9
   PubMed Web of Science ®Google Scholar
• Grainger DW. 2009. Nanotoxicity assessment: all small talk? Adv Drug Deliv Rev 61:419–21
   PubMed Web of Science ®Google Scholar
• Gulbranson SH, Had JA, Hansen RC. 2000. Argyria following the use of dietary supplements containing colloidal silver protein. Cutis 66:373–6
   PubMed Web of Science ®Google Scholar
• Hamburg MA. 2012. FDA’s approach to regulation of products of nanotechnology. Science 336:299–300
   PubMed Web of Science ®Google Scholar
• Hukkanen J, Jacob P, Peng M, Dempsey D, Benowitz NL. 2010. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Brit J Clin Pharmacol 69:152–9
   PubMed Web of Science ®Google Scholar
• Hussain SM, Hess KL, Gear hart JM, Geiss KT, Schlarger JJ. 2005. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19:975–83
   PubMed Web of Science ®Google Scholar
• Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. 2010. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 40:328–46
   PubMed Web of Science ®Google Scholar
• Kawata K, Osawa M, Okabe S. 2009. In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ Sci Techonol 43:6046–51
   PubMed Web of Science ®Google Scholar
• Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, et al. 2010. Subchronic oral toxicity of silver nanoparticles. Part Fibre Toxicol 7:20. doi: 10.1186/1743-8977-7-20
   PubMed Web of Science ®Google Scholar
• Klebanoff M, Levine R, DerSimonian R, Clemens J, Wilkens D. 1999. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 341:1639–89
   PubMed Web of Science ®Google Scholar
• Kolocouri F, Dotsikas Y, Apostolou C, Kousoulos C, Loukas YL. 2007. Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96 well-format-based solid-phase extraction and liquid chromatography-negative elcrospray tandem mass spectrometry. Anal Bioanal Chem 387:593–601
   PubMed Web of Science ®Google Scholar
• Kulthong K, Maniratanachote R, Kobayashi Y, Fukami T, Yokoi T. 2012. Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. Xenobiotica 42:854–62
   PubMed Web of Science ®Google Scholar
• Lamb JG, Hathaway LB, Munger MA, Raucy JL, Franklin MR. 2010. Nanosilver particle effects on drug metabolism in vitro. Drug Metab Dispos 38:2246–51
   PubMed Web of Science ®Google Scholar
• Li X, Chen X, Li Q, Wang L, Zhong D. 2007. Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tanden mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 852:128–37
   PubMed Web of Science ®Google Scholar
• Marier J-F, Dubuc M-C, Drouin E, Alvarez F, Ducharme MP, Brazier J-L. 2004. Pharmacokinetics of omeprazole in health adults and in children with gastroesophageal reflux disease. Ther Drug Monit 26:3–8
   PubMed Web of Science ®Google Scholar
• McKenna JK, Hull CM, Zone JJ. 2003. Argyria associated with colloidal silver supplementation. Int J Dermatol 42:549. doi: 10.1046/j.1365-4362.2003.01899.x
   PubMed Web of Science ®Google Scholar
• Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, et al. 2013. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine 10:1–9
   PubMed Web of Science ®Google Scholar
• Oberdörster G. 2010. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267:89–105
   PubMed Web of Science ®Google Scholar
• Ohkura K, Kawaguchi Y, Watanabe Y, Masubuchi Y, Shinohara Y, Hori H. 2009. Flexible structure of cytochrome P450 promiscuity of ligand binding in the CYP3A4 heme pocket. Anticancer Res 29:935–42
   PubMed Web of Science ®Google Scholar
• Otyepka M, Skopalik J, Anzenbacherová E, Anzenbacher P. 2007. What common structural features and variations of mammalian P450s are known to date? Biochem Biophys Acta 1770:376–89
   PubMed Web of Science ®Google Scholar
• Paek H-J, Lee Y-J, Chung H-E, Yoo N-H, Lee J-A, Kim M-K, et al. 2013. Modulation of the pharmacokinetics of zinc oxide nanoparticles and their fates in vivo. Nanoscale 5:11416–27
   PubMed Web of Science ®Google Scholar
• Roseman KD, Moss A, Kon S. 1979. Argyria: clinical implications of exposure to silver nitrate and silver oxide. J Occup Med 21:430–5
   PubMedGoogle Scholar
• Roy R, Hoover MR, Bhalla AS, Slawecki T, Dey S, Cao W, Li J, Bhaskar S. 2007. Ultradilute Ag-aquasols with extraordinary bacteriocidal properties: role of the system Ag–O–H2O. Mater Res Innovat 11:3–18
   Web of Science ®Google Scholar
• Samberg ME, Orndorff PE, Monteiro-Riviere, N. 2011. Antibacterial efficacy of silver nanoparticles of different sizes, surface conditions and synthesis methods. Nanotoxicol 5:244–53
   PubMed Web of Science ®Google Scholar
• Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schäffler M, et al. 2012. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology 6:36–46
   PubMed Web of Science ®Google Scholar
• Shelley WB, Shelley ED, Burmeister V. 1987. Argyria: the intradermal “photograph”, a manifestation of passive photosensitivity. J Am Acad Dermatol 16:211–17
   PubMed Web of Science ®Google Scholar
• Smock K, Schmidt R, Hadlock G, Stoddard G, Grainger DW, Munger MA. 2014. Assessment of orally dosed commercial silver nanoparticles on human ex vivo platelet aggregation. Nanotoxicology 8:328–33
   PubMed Web of Science ®Google Scholar
• Sung JH, Ji JH, Yun JU, Kim DS, Song MY, Jeong J, et al. 2008. Lung function changes in Sprague-Dawley rats after prolonged inhalation exposure to silver nanoparticles. Inhal Toxicol 20:567–74
   PubMed Web of Science ®Google Scholar
• Suzuki H, Baba S, Uchigasaki S, Murase M. 1993. Localized argyria with chrysiasis caused by implanted acupuncture needles. Distribution and chemical forms of silver and gold in cutaneous tissue by electron microscopy and x-ray microanalysis. J Am Acad Dermatol 29:833–7
   PubMed Web of Science ®Google Scholar
• Takenaka S, Karg E, Roth C, Schultz H, Ziesenis A, Heinzmann U, et al. 2001. Pulmonary and systemic distribution of inhaled ultrafine silver particles in rats. Environ Health Perspect 109:547–51
   PubMed Web of Science ®Google Scholar
• The Project on Emerging Nanotechnologies. Nanotech-enabled Consumer Products Continue to Rise. Available from: http://www.nanotechproject.org/news/archive/9231/ [Accessed on 24 May 2011]
   Google Scholar
• Villiers MM, Aramwit P, Kwon GS. 2009. Nanotechnology in Drug Delivery. New York, USA: Springer
   Google Scholar
• Wang J, Want Y, Fawcett JP, Wang Y, Gu J. 2004. Pharmacokinetics of omeprazole in healthy adults and children with gastroesophageal reflux. Ther Drug Monit 26:3–8
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu S, Ma J, Qu G, Wang X, Yu S, et al. 2013. Silver nanoparticles induced RNA polymerase-silver binding and RNA transcriptin inhibition in erythroid progenitor cells. ACS Nano 7:4171–86
   PubMed Web of Science ®Google Scholar
• Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, et al. 2004. Effect of the CYP 3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104–12
   PubMed Web of Science ®Google Scholar